-+ 0.00%
-+ 0.00%
-+ 0.00%

Hisco announced that the company's two new Class 1 drugs, cligabarin benzenesulfonate capsules and coglitin tablets, were included in the “National Medical Insurance Catalogue” and are all Class B drugs. Among them, cligabarin benzenesulfonate capsules are used to treat adult diabetic peripheral neuropathic pain and post-herpes zoster neuralgia. The agreement is valid from January 1, 2027 to December 31, 2028; coglitin tablets are used to improve blood sugar control in adult type 2 diabetics. This inclusion in medical insurance is conducive to the marketing of innovative pharmaceutical products and plays a positive role in product sales. The new medical insurance catalogue will be officially implemented on January 1, 2027.

Zhitongcaijing·11/16/2026 07:57:06
Listen to the news
Hisco announced that the company's two new Class 1 drugs, cligabarin benzenesulfonate capsules and coglitin tablets, were included in the “National Medical Insurance Catalogue” and are all Class B drugs. Among them, cligabarin benzenesulfonate capsules are used to treat adult diabetic peripheral neuropathic pain and post-herpes zoster neuralgia. The agreement is valid from January 1, 2027 to December 31, 2028; coglitin tablets are used to improve blood sugar control in adult type 2 diabetics. This inclusion in medical insurance is conducive to the marketing of innovative pharmaceutical products and plays a positive role in product sales. The new medical insurance catalogue will be officially implemented on January 1, 2027.